title: Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition.
abstract: A new structure-activity relationship model predicting the probability for a compound to inhibit human cytochrome P450 3A4 has been developed using data for >800 compounds from various literature sources and tested on PubChem screening data. Novel GALAS (Global, Adjusted Locally According to Similarity) modeling methodology has been used, which is a combination of baseline global QSAR model and local similarity based corrections. GALAS modeling method allows forecasting the reliability of prediction thus defining the model applicability domain. For compounds within this domain the statistical results of the final model approach the data consistency between experimental data from literature and PubChem datasets with the overall accuracy of 89%. However, the original model is applicable only for less than a half of PubChem database. Since the similarity correction procedure of GALAS modeling method allows straightforward model training, the possibility to expand the applicability domain has been investigated. Experimental data from PubChem dataset served as an example of in-house high-throughput screening data. The model successfully adapted itself to both data classified using the same and different IC₅₀ threshold compared with the training set. In addition, adjustment of the CYP3A4 inhibition model to compounds with a novel chemical scaffold has been demonstrated. The reported GALAS model is proposed as a useful tool for virtual screening of compounds for possible drug-drug interactions even prior to the actual synthesis.
authors.affiliation: ACD/Labs Inc., Vilnius, Lithuania.
authors.forename: Remigijus
authors.initials: R
authors.lastname: Didziapetris
authors.forename: Justas
authors.initials: J
authors.lastname: Dapkunas
authors.forename: Andrius
authors.initials: A
authors.lastname: Sazonovas
authors.forename: Pranas
authors.initials: P
authors.lastname: Japertas
mesh_terms: D001185:Artificial Intelligence; D017076:Computer-Aided Design; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D016208:Databases, Factual; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000706:statistics & numerical data*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008956:Models, Chemical; D021281:Quantitative Structure-Activity Relationship; D012984:Software; D014584:User-Computer Interface
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
references.citation: Biochemistry. 1998 Mar 24;37(12):4137-47
references.pmid: 9521735
references.citation: Clin Pharmacokinet. 2005;44(3):279-304
references.pmid: 15762770
references.citation: Drug Metab Dispos. 2001 May;29(5):748-53
references.pmid: 11302943
references.citation: Drug Metab Dispos. 2001 Nov;29(11):1473-9
references.pmid: 11602524
references.citation: J Med Chem. 2008 Feb 28;51(4):817-34
references.pmid: 18232648
references.citation: Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45
references.pmid: 16859410
references.citation: Drug Metab Dispos. 2001 Mar;29(3):282-8
references.pmid: 11181496
references.citation: Bioorg Med Chem. 2009 Aug 15;17(16):5906-19
references.pmid: 19632124
references.citation: J Biol Chem. 2004 Sep 10;279(37):38091-4
references.pmid: 15258162
references.citation: J Med Chem. 2008 Oct 9;51(19):5897-900
references.pmid: 18763755
references.citation: J Chem Inf Comput Sci. 2002 May-Jun;42(3):717-28
references.pmid: 12086534
references.citation: Drug Metab Dispos. 2004 Jun;32(6):647-60
references.pmid: 15155557
references.citation: J Biomol Screen. 2005 Apr;10(3):197-205
references.pmid: 15809315
references.citation: Nat Rev Drug Discov. 2005 Oct;4(10):825-33
references.pmid: 16224454
references.citation: J Comput Aided Mol Des. 2005 Mar;19(3):189-201
references.pmid: 16059671
references.citation: SAR QSAR Environ Res. 2004 Oct-Dec;15(5-6):345-58
references.pmid: 15669694
references.citation: Drug Metab Rev. 1997 Feb-May;29(1-2):413-580
references.pmid: 9187528
references.citation: J Chem Inf Model. 2006 Sep-Oct;46(5):2125-34
references.pmid: 16995743
references.citation: SAR QSAR Environ Res. 2010 Jan 1;21(1):127-48
references.pmid: 20373217
references.citation: J Med Chem. 2007 Feb 8;50(3):501-11
references.pmid: 17266202
references.citation: Xenobiotica. 2007 Mar;37(3):246-59
references.pmid: 17624023
references.citation: Drug Metab Dispos. 2000 Dec;28(12):1440-8
references.pmid: 11095581
references.citation: Eur J Pharm Sci. 2005 Apr;24(5):451-63
references.pmid: 15784335
references.citation: Drug Discov Today. 2005 Nov 1;10(21):1443-50
references.pmid: 16243264
references.citation: Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52
references.pmid: 10805063
references.citation: J Pharmacol Exp Ther. 1999 Jul;290(1):429-38
references.pmid: 10381809
references.citation: Eur J Med Chem. 2009 Jun;44(6):2354-60
references.pmid: 19026469
references.citation: Ann N Y Acad Sci. 2000;919:26-32
references.pmid: 11083094
references.citation: Drug Metab Dispos. 2003 Sep;31(9):1108-16
references.pmid: 12920166
references.citation: J Mol Graph Model. 2008 Jun;26(8):1315-26
references.pmid: 18328754
references.citation: Drug Metab Dispos. 2003 Sep;31(9):1077-80
references.pmid: 12920160
references.citation: Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13682-7
references.pmid: 16954191
references.citation: Bioorg Med Chem. 2009 Apr 15;17(8):3130-41
references.pmid: 19321349
references.citation: Br J Pharmacol. 1998 Feb;123(4):605-10
references.pmid: 9517377
references.citation: J Comput Aided Mol Des. 2007 Oct-Nov;21(10-11):559-73
references.pmid: 18034311
references.citation: Drug Metab Dispos. 2000 Mar;28(3):360-6
references.pmid: 10681383